XML 74 R46.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Investments in Group Enterprises (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Investments accounted for using equity method [abstract] |
Summary of Investments in Group Enterprises | Ascendis Pharma A/S’s (parent company) investments in group enterprises at December 31, 2024 comprise:
Subsidiaries |  | Domicile |  | Ownership |
Ascendis Pharma GmbH |  | Germany |  |  | 100 | %
Ascendis Pharma Endocrinology GmbH |  | Germany |  |  | 100 | %
Ascendis Pharma, Inc. |  | USA |  |  | 100 | %
Ascendis Pharma Endocrinology, Inc. |  | USA |  |  | 100 | %
Ascendis Pharma Ophthalmology Division A/S |  | Denmark |  |  | 100 | %
Ascendis Pharma Endocrinology Division A/S |  | Denmark |  |  | 100 | %
Ascendis Pharma Bone Diseases A/S |  | Denmark |  |  | 100 | %
Ascendis Pharma Growth Disorders A/S |  | Denmark |  |  | 100 | %
Ascendis Pharma Oncology Division A/S |  | Denmark |  |  | 100 | %
Ascendis Pharma Europe A/S |  | Denmark |  |  | 100 | %
Ascendis Pharma UK Limited |  | United Kingdom |  |  | 100 | %
Ascendis Pharma Iberia S.L. |  | Spain |  |  | 100 | %
Ascendis Pharma France SASU |  | France |  |  | 100 | %
Ascendis Pharma Italia SRL |  | Italy |  |  | 100 | %
Ascendis Pharma Sverige AB |  | Sweden |  |  | 100 | %
Ascendis Pharma Switzerland GmbH |  | Switzerland |  |  | 100 | %
Associates |  | Domicile |  | Ownership |
VISEN Pharmaceuticals |  | Cayman Island |  |  | 43.9 | %
Eyconis Inc. |  | USA |  |  | 41.6 | %

X
- Definition The disclosure of subsidiaries. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 16 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph B4 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration